Scientists at the Gladstone Institute of Neurological Disease (GIND) have identified the reason a key protein plays a major role in two neurodegenerative diseases.
In the current edition of the Journal of Neuroscience, researchers in the laboratory of GIND Associate Director Steven Finkbeiner, MD, PhD have found how the protein TDP-43 may cause the neurodegeneration associated with amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin-positive inclusion bodies (FTLDu). TDP-43, is the major component of protein aggregates in patients with these diseases. Mutations in the TDP-43 gene are also associated with familial forms of ALS and FTLDu.
"TDP-43 is a very exciting protein. We found that its location in the cell is a good indicator of the damage it may cause," said Finkbeiner, senior investigator and senior author on the study. "Our findings and our experimental model will allow further studies of this protein and how it results in disease."
Under normal circumstances, TDP-43 is a common protein that stays mostly in the nucleus. It has several beneficial functions, including binding DNA and RNA, inhibiting retroviruses, and helping with RNA splicing and nuclear body formation. It also shuttles mRNA to the cytoplasm.
However, in patients with ALS and FTLDu, TDP-43 is redistributed from the nucleus to the cytoplasm and forms insoluble TDP-43 aggregates in the nucleus, cytoplasm, or neuronal processes.
The Finkbeiner team developed a model system to find out how TDP-43 might be involved in neurodegenerative diseases. They used genetic engineering to add a fluorescent tag to normal or wildtype and mutant TDP-43 in rat neurons. The tag allowed them to easily see the intracellular location of the protein.
To determine the effects of the mutant protein, the researchers used an automated microscope that can examine hundreds of thousands of neurons individually over several days. With this large amount of data, they could use sophisticated statistical analyses to follow the fate of each individual neuron and determine its risk of death at any given time.
Their experimental system used primary neurons. These neurons are taken directly from an animal to a culture dish and provide the best cells for experiments because they retain many of the features of cells in the intact brain. In fact, Dr. Finkbeiner's system showed many "normal" features of TDP-43 in neurons. For example, wildtype TDP-43 was found in the nucleus in healthy neurons. Mutant TDP-43 was also found in the nucleus, but there was more of the protein in the cytoplasm.
Several neurons developed aggregates of the protein called inclusion bodies, which are often found in diseased neurons. In addition, the system can be easily manipulated by the investigators, making it a valuable tool for dissecting the biological mechanisms underlying diseases associated with TDP-43 deposition.
"We expect this system to be very helpful to other investigators," explained Finkbeiner.
The researchers found that the mutant TDP-43 was toxic to neurons and that more of it was found in the cytoplasm. Although the mutant protein formed inclusion bodies, these did not affect the risk of cell death. However, the amount of cytoplasmic TDP-43 was a strong and independent predictor of neuronal death. Using genetic manipulations, they showed that targeting wild-type TDP-43 to the cytoplasm is sufficient to recreate the toxicity associated with mutant TDP43. On the other hand, the toxic effect of the mutant protein could be blunted by preventing its export from the nucleus. It seems as if the toxicity of the mutation depends on cytoplasmic mislocalization of TDP-43.
"Our results indicate that the mutant protein is mislocalized to the cytoplasm," Finkbeiner said. "Although we don't know the underlying mechanism, the protein seems to become toxic in the cytoplasm and then causes death of the neuron."
Other members of the team were Dr. Gaia Skibinski, and Erica Korb from the Gladstone Institutes and Dr. Jane Wu and Elizabeth Rao from Northwestern University School of Medicine.
The research was supported by the National Institutes of Neurological Disorders and Stroke, the National Institute on Aging, and the Taube-Koret Center for Huntington's Disease Research.
Dr. Finkbeiner's primary affiliation is with the Gladstone Institute of Neurological Disease where his laboratory is located and his research is conducted. He is also Professor of Neurology and Physiology at the University of California, San Francisco, and Director of the Taube-Koret Center for Huntington's Disease Research. Drs. Barmada and Finkbeiner are also affiliated with the Consortium for Frontotemporal Dementia Research at the University of California, San Francisco.
About the Gladstone Institutes. The Gladstone Institutes is a nonprofit, independent research and educational institution, consisting of the Gladstone Institute of Cardiovascular Disease, the Gladstone Institute of Virology and Immunology and the Gladstone Institute of Neurological Disease. Independent in its governance, finances and research programs, Gladstone shares a close affiliation with UCSF through its faculty, who hold joint UCSF appointments.
Valerie Tucker | EurekAlert!
Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View
22.06.2018 | University of Sussex
New cellular pathway helps explain how inflammation leads to artery disease
22.06.2018 | Cedars-Sinai Medical Center
In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.
Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...
Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...
Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.
Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...
The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.
Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.
An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.
Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...
13.06.2018 | Event News
08.06.2018 | Event News
05.06.2018 | Event News
22.06.2018 | Materials Sciences
22.06.2018 | Earth Sciences
22.06.2018 | Life Sciences